Paul H. Seigel, M.D., F.A.C.C. Date of Birth: Marital Status: Married
PROFESSIONAL AFFILIATION: Baptist Hospital of Miami
Medical College of Virginia State University of New York at Binghamton POST GRADUATE TRAINING: Fellowship in Cardiovascular Medicine College of Medicine and Dentistry of New Jersey Residency in Internal Medicine
Page Two Paul H. Seigel, M.D., F.A.C.C. POST GRADUATE TRAINING CONTINUED. Internship in Internal Medicine
INVESTIGATIONS - RESEARCH:
Cardiovascular Research Center of South Florida
INVEST (Knoll Pharmaceuticals). Principal Investigator. This is an international clinical trial comparing a calcium antagonist (Verapamil Sinus rhythm) with a non-calcium antagonist treatment strategy (Atenolol) for the control of hypertension in patients with coronary artery disease. T.N.T. (Treating to New Targets) Parke-Davis/Pfizer. Principal Investigator. This study is to assess the CHD event reduction efficacy and safety of low-density lipoprotein cholesterol lowering to achieve LDL-C targets beyond currently recommended minimums when compared to only achieving the minimum.
Drug Used: Atorvistatin 10 mg up to 80 mg in the double-blind
CAMELOT (Pfizer, Inc). Principal Investigator. Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis. GUSTO IV (Eli Lily and Co). Principal Investigator. This is a post- MI study through the Cleveland Clinic. BRAVO: Blockade of the GP IIB/IIA Receptor to Avoid Vascular Occlusion. Principal Investigator. PRESTO: Prevention of REStenosis by Tranilast and its Outcomes. Principal Investigator. A phase III Double blind Placebo Controlled Trial of three doses of Tranilast (Protocol 004). MOXON TRIAL (Covance). Principal Investigator. STARSHIP (AstraZeneca) A 6 week, Randomized, open-Label, Comparative Sturdy to Evaluate the Efficacy and Safety of Rosuvastatin and Atirvastatin in the Treatment of Hypercholesterolemia in Hispanic Subjects.
Page Three Paul H. Seigel, M.D., F.A.C.C. INVESTIGATIONS – RESEARCH (continued):
ACTIVATE (SankyoPharma Development) A Randomized, Double-Blind placebo Controlled Study of the Efficacy and Safety of the ACAT inhibitorCS-505 versus Placebo for Reducing the Progression of Atherosclerosis in Subjects with Known Coronary Artery Disease Using Ultrasound (IVUS). EVEREST (Otsuka Pharmaceuticals) A Randomized, Double-blind Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure. CHARISMA (Sanofinsynthelabo and Bristal Myers Squibb Co.) Clopidogrel For High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance. CP-529, 414 (Pfizer) A Randomized, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin in Patients with Angiographically Documented Coronary Artery Disease. LUNAR (AstraZeneca) A 12-Week, Randomized, Open-Label, 3- Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes. NEB 302 (Bertek Pharmaceuticals) A Double-blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Dosing Study Evaluating the Effects of Nebivolol on Blood Pressure in Patients with Mild to Moderate Hypertension. NEB 306 (Bertek Pharmaceuticals) A Multi-Center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients with Mild to Moderate Hypertension. NEB 323 (Bertek Pharmaceuticals) A Multi-Center, Open Extension Study to Assess the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients with Mild to Moderate Hypertension. COMPELL (Kos Pharmaceuticals) An Open-Label, Comparative Efficacy Evaluation of Lipid Levels when Treated with Niaspan and Statin or Other Lipid-Modifying Therapies.
Page Four Paul H. Seigel, M.D., F.A.C.C. INVESTIGATIONS – RESEARCH (continued):
MDT3-003 (Labopharm) A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once a day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain due to Osteoarthritis of the Knee.
CERTIFICATIONS AND EXAMS:
Diplomate of the American Board of Internal Medicine -
Diplomate of the American Board of Cardiovascular Medicine -
Diplomate of National Board of Medical Examiners -
PRIVATE PRACTICE EXPERIENCE: James Bierfeld, M.D. Solo Practice Associates in Cardiology Miami Cardiology Group Managing Partner PROFESSIONAL ORGANIZATIONS: REFERENCES:
Toxicology and Applied Pharmacology 182, 55– 65 (2002) doi:10.1006/taap.2002.9427 Contribution of Dichloroacetate and Trichloroacetate to Liver TumorRichard J. Bull,*,†,2 Gayle A. Orner,* Rita S. Cheng,* Lisa Stillwell,* Anja J. Stauber,†Lyle B. Sasser,* Melissa K. Lingohr,† and Brian D. Thrall*,†* Molecular Biosciences Department, Pacific Northwest National Laboratory, Richland, W
Epidémiologie - Evolution naturelle - Diagnostic - Thérapie A. Bitton a , R.M.Müller b , S. Madersbacher c , U.E. Studer b Une meilleure compréhension de la pathogenèse, ainsi que de l’évolution naturelle de l’hyperplasie bénigne de la prostate (HBP), doublée de moyens diagnostiques et thérapeutiques plus performants, permettent, de nos jours, une meilleure prise en charge des pa